Sherry Aulin Biography and Net Worth

Ms. Aulin has served as our Chief Financial Officer since June 2021, and has led our finance function since June 2015, previously serving as our Vice President, Finance since March 2019. From 2011 until 2015, Ms. Aulin provided independent financial consulting and advisory services to various publicly-traded companies including Xenon where she supported the company through its initial public offering process. From 2004 to 2011, Ms. Aulin was at KPMG LLP, most recently as Senior Manager in the assurance practice, where she provided professional services to publicly-traded companies across various industries including in the life sciences sector. Ms. Aulin holds a BCom from the University of British Columbia and is a Chartered Professional Accountant, Chartered Accountant.

How old is Sherry Aulin?: Ms. Aulin is currently 41 years old. There are 7 older executives and no younger executives at Xenon Pharmaceuticals. The oldest executive at Xenon Pharmaceuticals is Ms. Shelley McCloskey B.A., Executive Vice President of Human Resources, who is 64 years old. Learn More on Sherry Aulin's age.
How do I contact Sherry Aulin?: The corporate mailing address for Ms. Aulin and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at investors@xenon-pharma.com. Learn More on Sherry Aulin's contact information.
Has Sherry Aulin been buying or selling shares of Xenon Pharmaceuticals?: Sherry Aulin has not been actively trading shares of Xenon Pharmaceuticals during the past quarter. Most recently, Sherry Aulin sold 18,709 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a transaction totalling $770,997.89. Learn More on Sherry Aulin's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes Sherry Aulin (CFO), James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 62,383 shares worth more than $2,535,891.27. The most recent insider tranaction occured on January, 27th when CEO Ian Mortimer sold 16,315 shares worth more than $660,757.50. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 1/27/2025.

Sherry Aulin Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/18/2024	Sell	18,709	$41.21	$770,997.89

Sherry Aulin Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $33.87

$33.62

$35.45

50 Day Range

MA: $38.01

$34.26

$40.45

2 Week Range

Now: $33.87

$33.27

$46.00

Volume

131,194 shs

Average Volume

378,074 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26